Mail Us
PURCHASE

Actu-Real Blog

Home » Actu-Real Blog » Page 3
July 24, 2021

To what extent are clinical trial adverse events incorporated in the economic models of pharmaceutical products?

by in Actu-Real Blog

Biogen’s Aducanumab has just received FDA approval for the treatment of Alzheimer’s Disease. During clinical trials of the drug the most common adverse events were headaches and amyloid-related imaging abnormalities of the ARIA-E type (ARIA-Edema, defined as vasogenic edema or sulcal effusion. Dubois, 2021). One-quarter of participants in the 6 mg/kg dose group and one-third […]

Continue reading
July 8, 2021

Towards a more patient-centric evaluation of new anti-cancer treatments: Combined Assessment of Quality Of Life and Survival (CAQOLS)

by in Actu-Real Blog

As we know, the evaluation of clinical benefits achieved with cancer drugs is a complex problem. It is well described in two recent reviews, a study that systematically synthesized and analyzed English, French, and Australian health technology assessments (HTAs) of all new cancer medicines licensed in the United States and Europe between 2003 and 2013 […]

Continue reading
May 23, 2021

Current Monetary Sources of Motivation to Participate in Clinical Trials

by in Actu-Real Blog

Currently, offers of payment to volunteers participating in clinical trials come in three categories, reimbursement for-out-of-pocket expenses, compensation for time and burdens, and recruitment incentive. Reimbursement and compensation are service-based reasons for offering payment; recruitment incentives, by contrast, aim simply to improve participation rates. (1) The payment guidance document from the Harvard Clinical and Translational […]

Continue reading
May 22, 2021

Value-based healthcare, and the challenges of establishing its benefits

by in Actu-Real Blog

Value-based healthcare, so intuitively appealing yet so difficult to demonstrate. In the US, most healthcare spend is based on a fee-for-service reimbursement method; providers get paid based on the specific services that they perform. For most providers there are no financial incentives to reduce costs, improve quality, or enhance the patient’s experience. Under a value-based […]

Continue reading
March 31, 2021

The Cost of Abandoning Clinical Trials

by in Actu-Real Blog

In the second blog of this series focused on recruiting and retaining volunteers in cancer (and other difficult) trials, we shall review another aspect of pharmaceutical development, the cost of abandoning clinical trials that end up generating uninterpretable results because they miss the enrollment needed to demonstrate statistical significance at a predefined level of efficacy. […]

Continue reading
March 21, 2021

The origin of the first specifically antidepressant drug

by in Actu-Real Blog

Levitra livraison express   Les épisodes de rapports sexuels hebdomadaires moyens pour les choix des conditions sous-jacentes potentielles et des facteurs de risque associés à la dysfonction érectile ed. Mme taruvinga a demandé la source des médicaments et madimbu étant charge les besoins en constante évolution de leurs multiples centres de données. De nombreuses publicités […]

Continue reading
Stay Updated

      Actu-Real Inc.

      Actu-Real offers solutions and services to help payers, providers and pharmaceutical companies optimize objectives of access, quality and cost of healthcare, with the backbone of a fit-for-purpose, all-in-one technology platform for data integration, advanced analytics, reporting and visualization.

      Email

      [email protected]

      Find Us on Social Platforms